Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 704-711

  Teng, R ^a   Butler, K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

drug drug interaction; enoxaparin; pharmacodynamic; pharmacokinetic; ticagrelor; unfractionated heparin

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; ENOXAPARIN; HEPARIN; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; YOUNG ADULT;

EID: 84868366539     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01367.x     Document Type: Article

References (44)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol, 2004; 44: E1-E211.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 2007; 116: e148-e304.
3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008; 29: 2909-2945.
4. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1598-1660.
5. van Giezen JJ, Humphries RG,. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost, 2005; 31: 195-204.
6. Teng R, Butler K,. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol, 2010; 66: 487-496.
7. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G,. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J, 2006; 27: 1038-1047.
8. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 2009; 120: 2577-2585.
9. van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost, 2009; 7: 1556-1565.
10. van Giezen JJJ, Berntsson P, Wissing BM,. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells. Arterioscler Thromb Vasc Biol, 2008; 28: e-72 (abst P207).
11. Teng R, Oliver S, Hayes MA, Butler K,. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos, 2010; 38: 1514-1521.
12. Butler K, Teng R,. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol, 2010; 70: 65-77.
13. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol, 2007; 50: 1844-1851.
14. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol, 2007; 50: 1852-1856.
15. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy. J Am Coll Cardiol, 2010; 56: 1456-1462.
16. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361: 1045-1057.
17. Rao SV, Ohman EM,. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv, 2010; 3: 80-88.
18. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L,. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest, 1980; 65: 64-73.
19. Thomson C, Forbes CD, Prentice CR,. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med, 1973; 45: 485-494.
20. Eika C,. The platelet aggregating effect of eight commercial heparins. Scand J Haematol, 1972; 9: 480-482.
21. Aggarwal A, Sobel BE, Schneider DJ,. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis, 2002; 13: 161-165.
22. Schneider DJ, Tracy PB, Mann KG, Sobel BE,. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation, 1997; 96: 2877-2883.
23. Sillen H, Cook M, Davis P,. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878: 2299-2306.
24. Food and Drug Administration. Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing and labeling recommendations. 2012. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf (accessed 13 June 2012).
25. Butler K, Teng R,. Evaluation and characterization of the ticagrelor effects on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther, 2012; 91: 264-271.
26. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ,. Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling. Blood, 2011; 117: 4946-4952.
27. Xiao Z, Theroux P,. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation, 1998; 97: 251-256.
28. Pleym H, Videm V, Wahba A, et al. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur J Cardiothorac Surg, 2006; 29: 933-940.
29. Westwick J, Scully MF, Poll C, Kakkar VV,. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res, 1986; 42: 435-447.
30. Burgess JK, Chong BH,. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol, 1997; 58: 279-285.
31. Aggarwal A, Whitaker DA, Rimmer JM, et al. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant, 2004; 19: 1559-1563.
32. Klein B, Faridi A, von Tempelhoff GF, Heilmann L, Mittermayer C, Rath W,. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res, 2002; 108: 291-296.
33. Caplain H, D'Honneur G, Cariou R,. Prolonged heparin administration during clopidogrel treatment in healthy subjects. Semin Thromb Hemost, 1999; 25 (Suppl 2): 61-64.
34. Eli Lilly & Co. Clinical study summary: study H7T-EW-TAAT. The effect of prasugrel on the pharmacodynamic response of unfractionated heparin in healthy subjects [CT registry ID# 8977; online]. 2008. Available at: http://www.lillytrials.com/results/Effient.pdf (accessed 13 June 2012).
35. Lidell C, Svedberg LE, Lindell P, Bandh S, Job B, Wallentin L,. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost, 2003; 89: 842-846.
36. Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J, 2010; 31: 1205-1211.
37. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost, 2000; 84: 891-896.
38. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost, 2007; 5: 2429-2436.
39. Beinema M, Brouwers JR, Schalekamp T, Wilffert B,. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost, 2008; 100: 1052-1057.
40. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G,. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol, 2004; 60: 173-182.
41. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos, 2008; 36: 1227-1232.
42. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther, 2007; 81: 735-741.
43. Small DS, Farid NA, Payne CD, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet, 2010; 49: 777-798.
44. Farid NA, Kurihara A, Wrighton SA,. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol, 2010; 50: 126-142.